Can a cancer drug stop liver tumors from returning after ablation?

NCT ID NCT06248554

Completed Disease control Sponsor: Chen Xiaoping Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is to see if it extends the time before the cancer returns or death occurs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1 inhibitor (a type of immunotherapy drug)
What this could lead to: If it works, this could offer a way to lower the chance of liver cancer coming back after standard ablation treatment.
What could go wrong: This is an early-phase study without a comparison group, so results are uncertain. Immunotherapy can cause side effects like fatigue, rash, or more serious immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Wuhan, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.